CY1119010T1 - Συνθεση και μεθοδος για τη θεραπευτικη αγωγη του διαβητη - Google Patents
Συνθεση και μεθοδος για τη θεραπευτικη αγωγη του διαβητηInfo
- Publication number
- CY1119010T1 CY1119010T1 CY20171100614T CY171100614T CY1119010T1 CY 1119010 T1 CY1119010 T1 CY 1119010T1 CY 20171100614 T CY20171100614 T CY 20171100614T CY 171100614 T CY171100614 T CY 171100614T CY 1119010 T1 CY1119010 T1 CY 1119010T1
- Authority
- CY
- Cyprus
- Prior art keywords
- diabetes
- treatment
- composition
- acid
- incretin
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 abstract 1
- 239000000859 incretin Substances 0.000 abstract 1
- 150000004668 long chain fatty acids Chemical class 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 210000005239 tubule Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14395109P | 2009-01-12 | 2009-01-12 | |
| US29377310P | 2010-01-11 | 2010-01-11 | |
| PCT/US2010/020629 WO2010081079A2 (en) | 2009-01-12 | 2010-01-11 | Composition and method for treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119010T1 true CY1119010T1 (el) | 2018-01-10 |
Family
ID=42317190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100614T CY1119010T1 (el) | 2009-01-12 | 2017-06-12 | Συνθεση και μεθοδος για τη θεραπευτικη αγωγη του διαβητη |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8470885B2 (enExample) |
| EP (1) | EP2376077B1 (enExample) |
| JP (1) | JP5702306B2 (enExample) |
| KR (4) | KR20170138573A (enExample) |
| CN (1) | CN102355896A (enExample) |
| AU (1) | AU2010203413B2 (enExample) |
| BR (1) | BRPI1006145B8 (enExample) |
| CA (1) | CA2748827C (enExample) |
| CL (1) | CL2011001692A1 (enExample) |
| CY (1) | CY1119010T1 (enExample) |
| DK (1) | DK2376077T3 (enExample) |
| EA (1) | EA022631B1 (enExample) |
| ES (1) | ES2628233T3 (enExample) |
| HR (1) | HRP20170886T1 (enExample) |
| HU (1) | HUE034551T2 (enExample) |
| LT (1) | LT2376077T (enExample) |
| MX (1) | MX2011007393A (enExample) |
| PL (1) | PL2376077T3 (enExample) |
| PT (1) | PT2376077T (enExample) |
| RS (1) | RS56054B1 (enExample) |
| SI (1) | SI2376077T1 (enExample) |
| SM (1) | SMT201700278T1 (enExample) |
| WO (1) | WO2010081079A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2364161B1 (en) * | 2008-11-26 | 2020-03-11 | Satiogen Pharmaceuticals, Inc. | Compositions containing satiogens and methods of use |
| US20150224081A1 (en) * | 2009-01-12 | 2015-08-13 | Biokier, Inc. | Composition and method for treatment of diabetes |
| WO2012151252A2 (en) * | 2011-05-02 | 2012-11-08 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US20220071895A1 (en) * | 2009-01-12 | 2022-03-10 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US9144586B2 (en) | 2010-04-07 | 2015-09-29 | Incube Labs, Llc | Method for treating glucose related disorders using stem cell-derived gastro-intestinal cells |
| WO2011143511A2 (en) | 2010-05-12 | 2011-11-17 | Columbia University | Methods for producing enteroendocrine cells that make and secrete insulin |
| KR20130055220A (ko) | 2011-11-18 | 2013-05-28 | 삼성전자주식회사 | 동박적층판 및 이를 사용한 금속코어기판의 제조방법 |
| JP6089042B2 (ja) * | 2011-11-21 | 2017-03-01 | エマウス メディカル インコーポレイテッド | 糖尿病及び関連症状の治療のための方法及び組成物 |
| US20150073057A1 (en) * | 2013-09-06 | 2015-03-12 | Biokier, Inc. | Composition and method for treatment of diabetes |
| EP3160503B1 (en) | 2014-06-26 | 2021-02-17 | The Trustees of Columbia University in the City of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
| CN114366802A (zh) * | 2015-04-22 | 2022-04-19 | 西达-赛奈医疗中心 | 用于治疗2型糖尿病的肠内递送的苦味寡肽 |
| WO2016210384A2 (en) | 2015-06-25 | 2016-12-29 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
| US9668991B1 (en) | 2015-12-09 | 2017-06-06 | International Business Machines Corporation | SCFA colonic composition |
| CN107684550B (zh) * | 2016-08-03 | 2020-04-10 | 徐天宏 | 糖尿病治疗产品及其制备与应用 |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| US20210084956A1 (en) | 2018-02-23 | 2021-03-25 | Ambra Bioscience Llc | Compositions and methods for hunger control and weight management |
| CN112839643A (zh) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | 用于治疗肌肉中脂肪浸润的组合物及方法 |
| CN114340615A (zh) | 2019-08-12 | 2022-04-12 | 麻省理工学院 | 用于施用治疗剂的制品和方法 |
| US20230190686A1 (en) * | 2021-12-17 | 2023-06-22 | Biokier, Inc. | Composition and method for treatment of diabetes |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA885473B (en) * | 1987-08-07 | 1989-03-29 | Century Lab Inc | Free fatty acids for treatment of diabetes mellitus |
| IT1245890B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
| WO1999007342A1 (en) | 1997-08-11 | 1999-02-18 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
| US6652882B1 (en) | 1997-10-06 | 2003-11-25 | Intellipharmaceutics Corp | Controlled release formulation containing bupropion |
| GB9722426D0 (en) | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
| IL142650A (en) | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| HK1046244B (zh) | 1999-06-14 | 2005-06-03 | 科斯默技术有限公司 | 控制释放与掩蔽味道的口服药物组合物 |
| DE60230591D1 (de) | 2001-02-26 | 2009-02-12 | Kissei Pharmaceutical | Glykopyranosyloxypyrazolderivate und deren medizinische verwendung |
| US20030203004A1 (en) * | 2002-04-24 | 2003-10-30 | Kelm Gary Robert | Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1506963B1 (en) | 2003-10-28 | 2005-04-13 | Adorkem Technology SpA | Method for the preparation of citalopram |
| ITMI20040187A1 (it) | 2004-02-06 | 2004-05-06 | Cosmo Spa | Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali |
| ITMI20041295A1 (it) | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
| JP2006056881A (ja) | 2004-07-21 | 2006-03-02 | Takeda Chem Ind Ltd | 縮合環化合物 |
| JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
| AU2006250354A1 (en) | 2005-05-23 | 2006-11-30 | Japan Tobacco Inc. | Pyrazole compound and therapeutic agent for diabetes comprising the same |
| DE102005046237A1 (de) * | 2005-09-28 | 2007-04-05 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen |
| ITMI20052000A1 (it) | 2005-10-21 | 2007-04-22 | Promefarm S R L | Compressa gastroresitente a base di butirrato di sodio |
| KR20080089494A (ko) | 2006-01-20 | 2008-10-06 | 스미스클라인 비참 코포레이션 | 화합물 |
| WO2008067219A2 (en) | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| CA2673054C (en) * | 2006-12-15 | 2016-05-10 | Tima Foundation | Novel compositions and uses thereof |
| EP2364161B1 (en) * | 2008-11-26 | 2020-03-11 | Satiogen Pharmaceuticals, Inc. | Compositions containing satiogens and methods of use |
| WO2010062861A2 (en) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| SG173612A1 (en) | 2009-02-10 | 2011-09-29 | Amarin Pharma Inc | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
| KR102012111B1 (ko) | 2009-06-15 | 2019-08-19 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
| BR122019016628B8 (pt) | 2009-09-23 | 2021-07-27 | Amarin Corp Plc | uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular |
-
2010
- 2010-01-11 EP EP10729620.4A patent/EP2376077B1/en active Active
- 2010-01-11 US US13/143,766 patent/US8470885B2/en active Active
- 2010-01-11 MX MX2011007393A patent/MX2011007393A/es active IP Right Grant
- 2010-01-11 JP JP2011545487A patent/JP5702306B2/ja active Active
- 2010-01-11 HU HUE10729620A patent/HUE034551T2/en unknown
- 2010-01-11 BR BRPI1006145A patent/BRPI1006145B8/pt not_active IP Right Cessation
- 2010-01-11 CN CN201080004432XA patent/CN102355896A/zh active Pending
- 2010-01-11 DK DK10729620.4T patent/DK2376077T3/en active
- 2010-01-11 KR KR1020177034790A patent/KR20170138573A/ko not_active Ceased
- 2010-01-11 RS RS20170584A patent/RS56054B1/sr unknown
- 2010-01-11 ES ES10729620.4T patent/ES2628233T3/es active Active
- 2010-01-11 KR KR1020117015982A patent/KR20110120866A/ko not_active Ceased
- 2010-01-11 SM SM20170278T patent/SMT201700278T1/it unknown
- 2010-01-11 KR KR1020197015093A patent/KR20190062609A/ko not_active Ceased
- 2010-01-11 CA CA2748827A patent/CA2748827C/en active Active
- 2010-01-11 WO PCT/US2010/020629 patent/WO2010081079A2/en not_active Ceased
- 2010-01-11 LT LTEP10729620.4T patent/LT2376077T/lt unknown
- 2010-01-11 AU AU2010203413A patent/AU2010203413B2/en not_active Ceased
- 2010-01-11 KR KR1020177007518A patent/KR20170034928A/ko not_active Ceased
- 2010-01-11 HR HRP20170886TT patent/HRP20170886T1/hr unknown
- 2010-01-11 EA EA201190068A patent/EA022631B1/ru unknown
- 2010-01-11 PL PL10729620T patent/PL2376077T3/pl unknown
- 2010-01-11 PT PT107296204T patent/PT2376077T/pt unknown
- 2010-01-11 SI SI201031473T patent/SI2376077T1/sl unknown
-
2011
- 2011-07-11 CL CL2011001692A patent/CL2011001692A1/es unknown
-
2012
- 2012-10-08 US US13/646,778 patent/US8680085B2/en active Active
-
2017
- 2017-06-12 CY CY20171100614T patent/CY1119010T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119010T1 (el) | Συνθεση και μεθοδος για τη θεραπευτικη αγωγη του διαβητη | |
| CY1123549T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
| BRPI0908421B8 (pt) | solução estável de um composto farmacêutico | |
| CY1120289T1 (el) | Συνθεσεις irna συστατικου c5 του συμπληρωματος και μεθοδοι χρησης αυτων | |
| CR20110204A (es) | Moleculas de anticuerpo mejoradas | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA201100299A1 (ru) | Органические соединения | |
| UA117570C2 (uk) | Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті | |
| CY1116029T1 (el) | Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 του 11-βητα υδροξυλ στεροειδους | |
| BR112015021838A2 (pt) | amatoxina, método de síntese, composição farmacêutica | |
| EA201190242A1 (ru) | Липидные композиции | |
| EA201290296A1 (ru) | Циклические пептиды, специфичные к рецептору меланокортина-1 | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| CY1119399T1 (el) | Aντι-dkk-1 αντισωματα | |
| EA201200977A1 (ru) | Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами | |
| CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
| CY1115736T1 (el) | Νεες συνθεσεις για αντιμετωπιση cmt και σχετικων διαταραχων | |
| BRPI1000320B8 (pt) | Composições e métodos para tratar sinais de envelhecimento da pele | |
| ECSP12011909A (es) | Derivados de glicósido y usos de los mismos | |
| MA32811B1 (fr) | Nouveaux composés | |
| EA201290158A1 (ru) | Композиция и способ лечения диабета | |
| EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции | |
| CY1117948T1 (el) | Μεθοδος επαγωγης ανοχης σε ενα αλλεργιογονο | |
| CY1121825T1 (el) | Αναστολεας φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου | |
| CY1120468T1 (el) | Εξανθρωπισμενα αντισωματα il-25 |